Predictmedix AI Showcases Innovative Impairment Screening Technology at a 30-Country Summit in India, Focusing on Combating Drug Addiction Globally
Predictmedix AI Showcases Innovative Impairment Screening Technology at a 30-Country Summit in India, Focusing on Combating Drug Addiction Globally
TORONTO, ON / ACCESSWIRE / November 2, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix"), a leading provider of rapid health screening solutions powered by proprietary artificial intelligence (AI) is proud to announce that it has been invited to the D-30 event to showcase its impairment screening technology, which is an international gathering of 30 nations focused on combating drug addiction on a global scale.
安大略省多伦多/ACCESSWIRE/2023年11月2日/由专有人工智能(AI)提供支持的快速健康筛查解决方案的领先提供商Predictmedix AI Inc.(CSE: PMED)(OTCQB: PMED)(FRA: 3QP)(“公司” 或 “Predictmedix”)自豪地宣布,它已受邀参加D-30活动,展示其减值筛查技术,即一次由30个国家组成的国际会议,重点是在全球范围内打击吸毒成瘾。
The D-30 event represents a significant milestone in the fight against drug addiction and disabilities caused by drug addiction, symbolizing the collaboration of 30 nations recognized by the United Nations for their dedicated efforts in tackling drug addiction on a global scale. The primary goal of the program is to draw attention to the pressing issue of drug abuse and foster international unity in addressing addiction.
D-30活动是打击吸毒成瘾和吸毒成瘾导致的残疾方面的一个重要里程碑,象征着30个国家的合作,这些国家因在全球范围内致力于解决吸毒成瘾问题而获得联合国的认可。该方案的主要目标是提请人们注意药物滥用这一紧迫问题,并在解决吸毒问题上促进国际团结。
The utility of Predictmedix technology is not only in identification of impairment (caused by alcohol or drugs such as cannabis) but also in managing the health of patients that are coming into addiction centers by monitoring their vital parameters in real-time and looking at trends for better management/diagnosis as they recover from the underlying drug addiction. Therefore the utility of the technology is both for de-addiction treatment and managing disability caused by it which is useful for patients, students, workers and the overall industry for creating a safer drug free world.
Predictmedix技术的用处不仅在于识别损伤(由酒精或大麻等药物引起),还可用于管理进入成瘾中心的患者的健康,方法是实时监控他们的重要参数,观察趋势,以便在他们从潜在的药物成瘾中恢复过来后更好地管理/诊断。因此,该技术的实用性既可以用于戒毒治疗,也可以管理由此造成的残疾,这对患者、学生、工人和整个行业都很有用,有助于创造一个更安全的无毒世界。
Details of the D-30 event are as follows:
D-30 活动的详细信息如下:
- Program: D-30, and Cultural Event
- Date: Saturday, November 4, 2023
- Time: 10:00 AM to 5:00 PM
- Venue: Hotel The Lalit, New Delhi, India
- 节目:D-30 和文化活动
- 日期:2023 年 11 月 4 日星期六
- 时间:上午10点至下午5点
- 地点:印度新德里拉利特酒店
Predictmedix AI will be actively involved in the event, showcasing its cutting-edge impairment screening technology, which has the potential to play a significant role in addressing drug addiction issues.
Predictmedix AI将积极参与此次活动,展示其尖端的缺陷筛查技术,该技术有可能在解决吸毒成瘾问题方面发挥重要作用。
Predictmedix has achieved over 90 per cent accuracy in identifying impaired individuals using a combination of multispectral imaging and speech analysis, as demonstrated in the company's latest study. As the technology is powered by artificial intelligence, its accuracy rate is only expected to increase with time, thanks to the deep learning and machine learning algorithms that allow the system to learn and adapt from new data.
该公司的最新研究表明,Predictmedix结合使用多光谱成像和语音分析在识别受损人群方面的准确率已达到90%以上。由于该技术由人工智能提供支持,其准确率预计只会随着时间的推移而提高,这要归功于允许系统学习和适应新数据的深度学习和机器学习算法。
Dr. Rahul Kushwah, COO of Predictmedix AI, expressed his enthusiasm for this opportunity: "We are excited to be participating in the D-30 event and we thank the organizers for inviting and showcasing our impairment screening technology in this global forum focusing on combating drug addiction globally. Predictmedix AI is committed to leveraging innovation to combat drug addiction and related issues, and this event aligns perfectly with our mission."
Predictmedix AI首席运营官Rahul Kushwah博士表达了他对这个机会的热情:“我们很高兴能参加D-30活动,也感谢组织者邀请并在这个以全球打击吸毒成瘾为重点的全球论坛上展示我们的缺陷筛查技术。Predictmedix AI致力于利用创新来对抗吸毒成瘾和相关问题,本次活动与我们的使命完全一致。”
Furthermore, Predictmedix AI is pleased to introduce Colonel G. Srikumar (Retd), an accomplished veteran of the Indian Army, as the new director of Predictmedix India Pvt Ltd. Colonel Srikumar has joined the company to accelerate business development in key sectors across India. His wealth of experience and dedication will contribute significantly to Predictmedix AI's growth and impact in the region. The utility of Predictmedix AI technology ranges from healthcare, sporting industry, workplace safety to defense segment and Colonel Srikumar will be assisting the company to accelerate business development in these segments in India along with key international markets in Africa and the Middle East.
此外,Predictmedix AI很高兴地介绍印度陆军退伍军人G. Srikumar上校(退役)为Predictmedix印度私人有限公司的新任董事。斯里库马尔上校加入该公司,以加快印度关键领域的业务发展。他丰富的经验和奉献精神将为Predictmedix AI在该地区的增长和影响做出重大贡献。Predictmedix AI技术的效用范围从医疗保健、体育行业、工作场所安全到国防领域,Srikumar上校将协助该公司加快印度这些领域以及非洲和中东主要国际市场的业务发展。
The Company will issue 62,250 common shares as consideration for the services provided by a marketing consultant to the Company. The shares will be subject to a hold period of 4 months from the date of issuance.
公司将发行62,250股普通股,作为营销顾问向公司提供服务的对价。自发行之日起,这些股票的持有期为4个月。
About Predictmedix AI Inc.
关于 Predictmedix AI Inc.
Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn. To receive company news, please sign up for alerts on
Predictmedix AI Inc.(CSE: PMED)(OTCQB: PMEDF)(FRA: 3QP)是全球快速健康筛查和远程患者护理解决方案的新兴提供商。该公司的安全入境站由专有的人工智能(AI)提供支持,使用多光谱摄像机分析生理数据模式并预测各种健康问题,包括19种生理生命参数、药物或酒精损害、疲劳或各种精神疾病。Predictmedix AI 专有的远程患者护理平台为医疗专业人员提供了一套人工智能驱动的工具,以改善患者的健康状况。要了解更多信息,请访问我们的网站或在推特、Instagram或领英上关注我们。要接收公司新闻,请注册以下提醒
Public Relations Contact
公共关系联系人
For further media information or to set up an interview, please contact:
欲了解更多媒体信息或安排采访,请联系:
Nelson Hudes
Communications International (905) 660 9155
Nelson@hudescommunications.com
Dr. Rahul Kushwah (647) 889 6916
纳尔逊·哈德斯
通信国际 (905) 660 9155
Nelson@hudescommunications.com
Rahul Kushwah 博士 (647) 889 6916
Caution Regarding Forward-Looking Information:
关于前瞻性信息的注意事项:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.
本新闻稿可能包含基于当前预期的前瞻性陈述和信息。这些陈述不应被视为对公司未来业绩或业绩的保证。此类陈述涉及已知和未知的风险、不确定性和其他因素,可能导致实际结果、业绩或成就与此类陈述所暗示的存在重大差异。尽管此类陈述基于管理层的合理假设,但无法保证此类假设会被证明是正确的。我们不承担更新或修改它们以反映新事件或情况的责任。本公司的证券未根据经修订的1933年《美国证券法》(“美国证券法”)或适用的州证券法进行注册,在未进行注册或未获得此类注册要求的适用豁免的情况下,不得向美国个人或 “美国人” 发行或出售,或为其账户或利益进行发行或出售,如《美国证券法条例》中定义的那样。本新闻稿不应构成卖出要约或征求买入要约,在美国或任何此类要约、招揽或出售为非法的司法管辖区,也不得出售任何证券。此外,还有一些已知和未知的风险因素可能导致公司的实际业绩、业绩或成就与本文所含前瞻性信息所表达或暗示的未来业绩、业绩或成就存在重大差异,例如但不限于依赖获得监管部门的批准;获得与其技术相关的知识产权的能力;有限的经营历史;一般业务、经济、竞争、政治、监管和社会不确定性,以及特别是,与 COVID-19 相关的不确定性;与公司无法控制的因素相关的风险,包括与 COVID-19 相关的风险;与公司股票相关的风险,包括由该方可能或可能无法控制的事件导致的价格波动;对管理层的依赖;以及该行业其他竞争对手的紧急情况。
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
本文中的所有前瞻性信息均受本警示声明的全面限制,除非法律要求,否则公司不承担任何修改或更新任何此类前瞻性信息或公开宣布为反映未来业绩、事件或发展而对本文包含的任何前瞻性信息进行任何修订的结果的义务。
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
免责声明:“公司目前并未明确或暗示其产品有能力诊断、消除、治愈或遏制 COVID-19(或 SARS-2 冠状病毒)。
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
加拿大证券交易所尚未对本新闻稿的充分性或准确性进行审查,也不承担任何责任。
SOURCE: Predictmedix AI Inc.
来源:Predictmedix AI Inc.